However, total tumor-infiltrating CD8 T cells did not correlate well with the objective tumor response to nivolumab in patients with advanced hepatocellular carcinoma (HCC; CheckMate 040 study) [2]. Here, CD8A is linked to hepatocellular carcinoma.